Myeloid Malignancy

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Germline Testing for Predisposition to Myeloid Malignancies

Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

A Telehealth Advance Care Planning Intervention

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

A Study of GLB-001 in Patients With Myeloid Malignancies

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML